NanoValent and NanoSmart Enter Strategic Research Collaboration to...
NanoSmart and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration agreement to explore the feasibility of jointly developing an ANA-conjugated liposomal doxorubicin nanoparticle for the treatment of ovarian cancer and other solid tumors.
Research Conducted at Korea University Has Updated Our Knowledge about Cancer Therapy
Editor at Biotech Week -- Fresh data on Oncology are presented in a new report. According to news reporting originating from , by NewsRx correspondents, research stated, "We have designed and evaluated coacervate microcapsules-immobilized multilayer sodium alginate beads for oral drug delivery.
Wed Apr 16, 2014
Study Data from Tufts University Provide New Insights into Drug Delivery Systems
Editor at Biotech Week -- Research findings on Drugs and Therapies are discussed in a new report.
Researchers from Pasteur Institute Report Findings in Doxorubicin Therapy
Results indicated that the effect of NPs on cancer cells killing is dose-dependent, optimized at 1.25 g/L.
Drug-delivering nanoparticles pose a triple threat to cancer
MIT's new nanoparticle carries three cancer-fighting drug molecules - doxorubicin is red, the small green particles are camptothecin, and the larger green core contains cisplatin Delivering drugs that can knock out tumor cells within the body, without causing adverse side effects, is a tricky busines.
Magnets Lure Multi-Drug Ferrying Nanoparticles to Tumors for Targeted Combination Chemo Therapy
The new MIT nanoparticles consist of polymer chains and three different drug molecules - doxorubicin is red, the small green particles are camptothecin, and the larger green core contains cisplatin.
Dosing initiated in Phase I/II clinical trial of APR-246 in ovarian cancer
Aprea is a Karolinska Development AB portfolio company. Cancers develop and spread due to the malfunction of the cells' normal growth control mechanisms.
Thu Apr 10, 2014
Researchers from University of Delaware Report Recent Findings in Polyethylene Glycols
In this study, a hydrogel-derived prostate cancer model was developed for the in vitro evaluation of doxorubicin -loaded polymer NPs ."
New Drug Delivery Systems Findings from Zhengzhou University Described
Herein, we developed a doxorubicin -loaded poly derivatized fullerene to facilitate combined chemotherapy and photodynamic therapy in one system, and DOX was covalently conjugated onto C60-PEI by the pH-sensitive hydrazone linkage."
Wed Apr 09, 2014
Puma Biotechnology Presents Positive PB272 Phase II Data from I-SPY 2 TRIAL
The I-SPY 2 TRIAL is a randomized Phase II clinical trial for women with newly diagnosed Stage 2 or higher breast cancer that addresses whether adding investigational drugs to standard chemotherapy in the neoadjuvant setting is better than standard chemotherapy.
Celsion announces data supporting development of ThermoDox
Celsion announces data supporting development of ThermoDox Celsion announced that data supporting the development of ThermoDox, its proprietary heat-activated liposomal encapsulation of doxorubicin, plus high intensity focused ultrasound were presented at the International Symposium on Therapeutic Ultrasound.
Mon Apr 07, 2014
Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL
The presentation entitled 'Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL' was presented today at the session entitled 'Clinical Trials Symposium: Biomarker Driven Clinical Trials.'
Thu Apr 03, 2014
Biodegradable Magnetic Nanocarrier for Stimuli Responsive Drug Release
Biocompatible nanocarriers conjugated with magnetic nanoparticle, doxorubicin and poly motif have been designed to create a magnetic vector under magnetic field.
CytRx to Present Updated Aldoxorubicin Preclinical Glioblastoma Study ...
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that positive preclinical results from an in vivo study of aldoxorubicin in an animal model of glioblastoma will be presented at the American Association for Cancer Research Annual Meeting being held April 5-9, 2014 in San Diego, CA.
Study Findings from Isfahan University of Technology Broaden Understanding of Immunoglobulins
Scanning electron microscopy and atomic force microscopy were employed for characterization of the various layers that were formed at the electrode surface."
Wed Apr 02, 2014
Researchers from University of Coimbra Describe Findings in Cancer Gene Therapy
Plasmid DNA and an anticancer drug, doxorubicin , could both be loaded with high encapsulation efficiency and released from pDNA microgels; quite relevant is also the less toxic effect of the incorporated drug, as compared with naked DOX."
Nongenotoxic effects and a reduction of the DXR-induced genotoxic...
This research evaluated the genotoxicity of oil and tincture of H. annuus L. seeds using the micronucleus assay in bone marrow of mice.
New Cancer Therapy Study Findings Reported from Hanyang University
In this study, layer-by-layer nanoarchitectures were prepared by step-wise deposition of naturally derived chitosan and hyaluronic acid on negatively charged hybrid solid lipid nanoparticles ."